Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Dec 1.

Published in final edited form as: Neuropharmacology. 2015 Jun 24;99:369–378. doi: 10.1016/j.neuropharm.2015.06.011

Table 2.

A. Circulating Sertraline and Desmethylsertraline and CSF 5-hydroxyindole acetic acid (5-HIAA)^a
	Placebo		Sertraline
	Baseline	Treatment	Baseline	Treatment
Plasma Sertraline	-----	-----	------	132.0 (19.8)
Plasma Desmethylsertraline	-----	-----	------	182.0 (30.0)
CSF 5-HIAA	44.9 (3.5)	44.8 (3.1)	46.2 (3.7)^b	26.6 (2.38)^b

B. Effects of Sertraline on Behavioral Indicators of Depression and Anxiety^c
	Placebo		Sertraline
	Baseline	Treatment	Baseline	Treatment	Phase X Treatment
Depressive Behavior	1.06 (0.37)	2.58 (0.69)	0.69 (0.37)	2.96 (0.69)	F[1,40]=0.64, p=0.43
Anxious Behavior	42.5 (4.10)	41.8 (2.83)	43.2 (4.06)	35.4 (2.80)	F[1,40]=4.40, p=0.04

^a

Mean (SEM) in ng/ml; CSF: Cerebrospinal fluid

^b

t(20) = 9.97, p < 0.000001

^c

Mean (SEM) in frequency/hour